# Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

> **NCT01802450** · PHASE2 · UNKNOWN · sponsor: **PETHEMA Foundation** · enrollment: 18 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01802450
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2015-06
- **Final completion:** 2016-12
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-09-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802450, "Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase". Retrieved via AI Analytics 2026-06-06 from https://api.ai-analytics.org/clinical/NCT01802450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*